BACKGROUND: Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive rat F98 gliomas and human U87 glioma xenografts after treatment with the nitrone compound OKN-007, a disulfonyl derivative of α-phenyl-tert-butyl nitrone. METHODS: MRI was used to assess tumor volumes in F98 and U87 gliomas, and bioluminescence imaging was used to measure tumor volumes in F98 gliomas encoded with the luciferase gene (F98(luc)). Immunohistochemistry was used to assess angiogenesis (vascular endothelial growth factor [VEGF] and microvessel density [MVD]), cell differentiation (carbonic anhydrase IX [CA-IX]), hypoxia (hypoxia-inducible factor-1α [HIF-1α]), cell proliferation (glucose transporter 1 [Glut-1] and MIB-1), proliferation index, and apoptosis (cleaved caspase 3) markers in F98 gliomas. VEGF, CA-IX, Glut-1, HIF-1α, and cleaved caspase 3 were assessed in U87 gliomas. RESULTS: Animal survival was found to be significantly increased (P < .001 for F98, P < .01 for U87) in the group that received OKN-007 treatment compared with the untreated groups. After MRI detection of F98 gliomas, OKN-007, administered orally, was found to decrease tumor growth (P < .05). U87 glioma volumes were found to significantly decrease (P < .05) after OKN-007 treatment, compared with untreated animals. OKN-007 administration resulted in significant decreases in tumor hypoxia (HIF-1α [P < .05] in both F98 and U87), angiogenesis (MVD [P < .05], but not VEGF, in F98 or U87), and cell proliferation (Glut-1 [P < .05 in F98, P < .01 in U87] and MIB-1 [P < .01] in F98) and caused a significant increase in apoptosis (cleaved caspase 3 [P < .001 in F98, P < .05 in U87]), compared with untreated animals. CONCLUSIONS: OKN-007 may be considered as a promising therapeutic addition or alternative for the treatment of aggressive human gliomas.
BACKGROUND:Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive ratF98 gliomas and humanU87glioma xenografts after treatment with the nitrone compound OKN-007, a disulfonyl derivative of α-phenyl-tert-butyl nitrone. METHODS: MRI was used to assess tumor volumes in F98 and U87gliomas, and bioluminescence imaging was used to measure tumor volumes in F98 gliomas encoded with the luciferase gene (F98(luc)). Immunohistochemistry was used to assess angiogenesis (vascular endothelial growth factor [VEGF] and microvessel density [MVD]), cell differentiation (carbonic anhydrase IX [CA-IX]), hypoxia (hypoxia-inducible factor-1α [HIF-1α]), cell proliferation (glucose transporter 1 [Glut-1] and MIB-1), proliferation index, and apoptosis (cleaved caspase 3) markers in F98 gliomas. VEGF, CA-IX, Glut-1, HIF-1α, and cleaved caspase 3 were assessed in U87gliomas. RESULTS: Animal survival was found to be significantly increased (P < .001 for F98, P < .01 for U87) in the group that received OKN-007 treatment compared with the untreated groups. After MRI detection of F98 gliomas, OKN-007, administered orally, was found to decrease tumor growth (P < .05). U87glioma volumes were found to significantly decrease (P < .05) after OKN-007 treatment, compared with untreated animals. OKN-007 administration resulted in significant decreases in tumor hypoxia (HIF-1α [P < .05] in both F98 and U87), angiogenesis (MVD [P < .05], but not VEGF, in F98 or U87), and cell proliferation (Glut-1 [P < .05 in F98, P < .01 in U87] and MIB-1 [P < .01] in F98) and caused a significant increase in apoptosis (cleaved caspase 3 [P < .001 in F98, P < .05 in U87]), compared with untreated animals. CONCLUSIONS:OKN-007 may be considered as a promising therapeutic addition or alternative for the treatment of aggressive humangliomas.
Authors: Johan Wemer; Yi-Fang Cheng; Dag Nilsson; Ingalill Reinholdsson; Bo Fransson; Kerstin Lanbeck Vallén; Lars Nyman; Catarina Eriksson; Staffan Björck; Sam Schulman Journal: Curr Med Res Opin Date: 2006-09 Impact factor: 2.580
Authors: David L Gillespie; Kum Whang; Brian T Ragel; Jeannette R Flynn; David A Kelly; Randy L Jensen Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Jeannette R Flynn; Libo Wang; David L Gillespie; Gregory J Stoddard; Jason K Reid; Jason Owens; Grant B Ellsworth; Karen L Salzman; Anita Y Kinney; Randy L Jensen Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Kader Yagiz; Tiffany T Huang; Fernando Lopez Espinoza; Daniel Mendoza; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly; Joan M Robbins Journal: Neuro Oncol Date: 2016-05-10 Impact factor: 12.300
Authors: Patricia Coutinho de Souza; Krithika Balasubramanian; Charity Njoku; Natalyia Smith; David L Gillespie; Andrea Schwager; Osama Abdullah; Jerry W Ritchey; Kar-Ming Fung; Debra Saunders; Randy L Jensen; Rheal A Towner Journal: J Magn Reson Imaging Date: 2015-04-29 Impact factor: 4.813
Authors: Patricia Coutinho de Souza; Nataliya Smith; Oluwatomisin Atolagbe; Jadith Ziegler; Charity Njoku; Megan Lerner; Marilyn Ehrenshaft; Ronald P Mason; Bill Meek; Scott M Plafker; Debra Saunders; Nadezda Mamedova; Rheal A Towner Journal: Free Radic Biol Med Date: 2015-06-26 Impact factor: 7.376
Authors: Patricia Coutinho de Souza; Nataliya Smith; Richard Pody; Ting He; Charity Njoku; Robert Silasi-Mansat; Florea Lupu; Bill Meek; Hong Chen; Yunzhou Dong; Debra Saunders; Albert Orock; Erik Hodges; Sarah Colijn; Nadezda Mamedova; Rheal A Towner Journal: Am J Nucl Med Mol Imaging Date: 2015-06-15
Authors: Megan Stiles; Gennadiy P Moiseyev; Madeline L Budda; Annette Linens; Richard S Brush; Hui Qi; Gary L White; Roman F Wolf; Jian-Xing Ma; Robert Floyd; Robert E Anderson; Nawajes A Mandal Journal: PLoS One Date: 2015-12-22 Impact factor: 3.240